Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by wexworthon Oct 30, 2020 12:23pm
182 Views
Post# 31813444

Its starting

Its starting
The dermatology community apparently was a little slow to know about and respond to the implications of the Cares Act. Its starting to make sense why a broader segment of investors haven't figured it out - the Dermatologists are just hearing about it as we speak. Looks like there is plenty of unexplored runway to generate some awareness on the importance of TFC 1067. Hopefully we will get some form of notable mention by Rodan of the importance of the product when they decide to launch. For the life of me I can't figure out why Sirona is not shouting from the rooftops at the community to generate draw here. I guess the Rodan launch will be just as much of a market introduction for them as it will be for Sirona. Where is the Hydroquinone? Regulatory Change Hinders Access / OCTOBER 29, 2020 https://practicaldermatology.com/news/where-is-the-hydroquinone-regulatory-change-hinders-access?c4src=home:feed "Changes to FDA regulations implemented as part of the CARES Act this spring have left dermatologists and their patients scrambling to access hydroquinone."
<< Previous
Bullboard Posts
Next >>